These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35432811)

  • 1. Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer.
    Razzaghdoust A; Muhammadnejad S; Parvin M; Mofid B; Zangeneh M; Basiri A
    Iran J Basic Med Sci; 2021 Dec; 24(12):1650-1655. PubMed ID: 35432811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
    Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
    Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.
    Villanueva H; Wells GA; Miller MT; Villanueva M; Pathak R; Castro P; Ittmann MM; Sikora AG; Lerner SP
    Heliyon; 2022 Dec; 8(12):e12570. PubMed ID: 36643309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
    Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
    J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
    Lang H; Béraud C; Cabel L; Fontugne J; Lassalle M; Krucker C; Dufour F; Groeneveld CS; Dixon V; Meng X; Kamoun A; Chapeaublanc E; De Reynies A; Gamé X; Rischmann P; Bieche I; Masliah-Planchon J; Beaurepere R; Allory Y; Lindner V; Misseri Y; Radvanyi F; Lluel P; Bernard-Pierrot I; Massfelder T
    Front Oncol; 2022; 12():930731. PubMed ID: 36033544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer.
    Razzaghdoust A; Ghajari M; Basiri A; Torbati PM; Jafari A; Fattahi MR; Salahi M; Mofid B
    Investig Clin Urol; 2021 May; 62(3):274-281. PubMed ID: 33943049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-derived bladder cancer xenograft models reveal VEGF and CDK4 enhancing tumor metastasis behavior.
    Zhao Y; An M; Zhang H; Tan D; Chen X; Wu P; Qin W; Zhang C; Shi C
    RSC Adv; 2019 Jun; 9(31):17877-17884. PubMed ID: 35520551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer.
    Fang T; Huang H; Li X; Liao J; Yang Z; Hoffman RM; Cheng XI; Liang L; Hu W; Yun S
    Anticancer Res; 2018 Jan; 38(1):179-186. PubMed ID: 29277771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Jütte H; Reike M; Wirtz RM; Kriegmair M; Erben P; Tully K; Weyerer V; Eckstein M; Hartmann A; Eidt S; Wezel F; Bolenz C; Tannapfel A; Noldus J; Roghmann F
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34073233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
    Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
    J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib.
    Lee AQ; Ijiri M; Rodriguez R; Gandour-Edwards R; Lee J; Tepper CG; Li Y; Beckett L; Lam K; Goodwin N; Satake N
    Front Oncol; 2021; 11():648097. PubMed ID: 33842362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and application of patient-derived xenograft mice model of colorectal cancer.
    Zhang Y; Yang Y; Zan L; Wang J; Yan L; Zhao L; Chen L; Xi Y; Bai W; Yang X
    Iran J Basic Med Sci; 2023 Feb; 26(2):248-254. PubMed ID: 36742145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.
    Dong R; Qiang W; Guo H; Xu X; Kim JJ; Mazar A; Kong B; Wei JJ
    J Hematol Oncol; 2016 Sep; 9(1):92. PubMed ID: 27655386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study.
    Yu X; Chen Y; Lu J; He K; Chen Y; Ding Y; Jin K; Wang H; Zhang H; Wang H; Teng L
    Front Oncol; 2022; 12():985154. PubMed ID: 36465411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer.
    Xu W; Zhao ZY; An QM; Dong B; Lv A; Li CP; Guan XY; Tian XY; Wu JH; Hao CY
    Int J Med Sci; 2020; 17(18):3073-3081. PubMed ID: 33173428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
    Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
    Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization.
    Miyamoto S; Tanaka T; Hirosuna K; Nishie R; Ueda S; Hashida S; Terada S; Konishi H; Kogata Y; Taniguchi K; Komura K; Ohmichi M
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.